Global Diabetic Retinopathy Market 2012-2016

Global Diabetic Retinopathy Market 2012-2016

Category : Healthcare

TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

TechNavio's analysts forecast the Global Diabetic Retinopathy Market to grow at a CAGR of 35.22 percent over the period 2012-2016. One of the key factors contributing to this market growth is the Increase in Diabetic Population Worldwide. The Global Diabetic Retinopathy Market has also been witnessing the Increased Focus on Combination Therapies. However, the Availability of Effective Surgical Treatments could pose a challenge to the growth of this market. 
TechNavio's report, the Global Diabetic Retinopathy Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC region; it also covers the Global Diabetic Retinopathy market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this space include Eli Lilly and Co., Novartis International AG, Pfizer Inc., and Roche Holding Ltd.
Other vendors mentioned in the report are Alcon Inc., Allergan Inc., Ampio Pharmaceuticals Inc., Anadys Pharmaceuticals Inc., Antisense Therapeutics Ltd., Boehringer Ingelheim GmbH, DeveloGen AG, Excaliard Pharmaceuticals Inc., Eyetech Inc., Ferrosan Holding A/S, FoldRx Pharmaceuticals Inc., iCo Therapeutics Inc., Intercell AG, Isis Pharmaceuticals Inc., King Pharmaceuticals Inc., Lpath Inc., Lupin Ltd., mtm laboratories AG, Novagali Pharma SA, Novast Laboratories Ltd., OPKO Health Inc., PAREXEL International Corp., pSivida Corp., Quark Pharmaceuticals Inc., Sirnaomics Inc., ThromboGenics NV, Torrent Pharmaceuticals Ltd., and Vitreoretinal Technologies Inc.
Key questions answered in this report:
What will the market size be in 2016 and at what will be the growth rate?
What are key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by key vendors?
What are the strengths and weaknesses of each of these key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details provided within the report.

 

01. Executive Summary

02. List of Abbreviations

03. Introduction

04. Scope of the Report


Business Overview

04.1 Product Offerings

05. Market Landscape

Market Size and Forecast

05.1Five Force Analysis

06. Geographical Segmentation

07. Vendor Landscape

08. Buying Criteria

09. Diabetic Retinopathy Drugs in the Pipeline

10. Market Growth Drivers

11. Drivers and their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Key Vendor Analysis


15.1 Roche Holding Ltd.

Business Overview

Key Information

SWOT Analysis

15.2 Novartis International AG.

Business Overview

Key Information 

 SWOT Analysis

15.3 Pfizer Inc.

Business Overview

Key Information

SWOT Analysis

      15.4 Eli Lilly and Co.

Business Overview

Key Information

SWOT Analysis

16. Other Reports in this Series 



List of Exhibits:



Exhibit 1:     Global Diabetic Retinopathy Drugs Market 2012-2016(US$ million)

Exhibit 2: Global Diabetic Retinopathy Drugs Market by Geographical Segmentation 2012

Exhibit 3: Business Segmentation of Roche Holding Ltd

Exhibit 4: Business Segmentation of Novartis International AG

Exhibit 5: Business Segmentation of Pfizer Inc.

Exhibit 6: Business Segmentation of Eli Lilly and Co.


Enquiry Before Buy
image
Can´t read the image ? refresh here.